📣 VC round data is live. Check it out!
- Public Comps
- Quanterix
Quanterix Valuation Multiples
Discover revenue and EBITDA valuation multiples for Quanterix and similar public comparables like Zepp Health, Nyxoah, NN, Paxman and more.
Quanterix Overview
About Quanterix
Quanterix Corp is a life sciences company that focuses on developing an ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics. The Simoa bead-based and planar array platforms designed by the company enable customers to reliably detect protein biomarkers in low concentrations in blood, serum, and other fluids that are undetectable using conventional, analog immunoassay technologies. Its products include Simoa, Assay Kits, LDTs & Assay Services, Simoa p-Tau 217, Simoa NfL LDT, Simoa p-Tau 181 LDT, Instruments, HD-X Automated Immunoassay Analyzer, SR-X Biomarker Detection System, SP-X Imaging and Analysis System, Simoa Accelerator Laboratory and others. Geographically, It operates in North America, EMEA and Asia Pacific.
Founded
2007
HQ

Employees
136
Website
Financials (LTM)
EV
$63M
Valuation Multiples
Start free trialQuanterix Financials
Quanterix reported last 12-month revenue of $151M and negative EBITDA of ($38M).
In the same LTM period, Quanterix generated $73M in gross profit, ($38M) in EBITDA losses, and had net loss of ($88M).
Revenue (LTM)
Quanterix P&L
In the most recent fiscal year, Quanterix reported revenue of $139M and EBITDA of ($45M).
Quanterix is unprofitable as of last fiscal year, with gross margin of 47%, EBITDA margin of (32%), and net margin of (77%).
Financial data powered by Morningstar, Inc.
Quanterix Stock Performance
Quanterix has current market cap of $127M, and enterprise value of $63M.
Market Cap Evolution
Quanterix's stock price is $2.69.
Quanterix share price decreased by 14.1% in the last 30 days, and by 48.3% in the last year.
Quanterix has an EPS (earnings per share) of $-2.27.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $63M | $127M | 0.0% | -14.1% | -58.7% | -48.3% | $-2.27 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialQuanterix Valuation Multiples
Quanterix trades at 0.4x EV/Revenue multiple, and (1.6x) EV/EBITDA.
EV / Revenue (LTM)
Quanterix Financial Valuation Multiples
As of May 26, 2026, Quanterix has market cap of $127M and EV of $63M.
Quanterix has a P/E ratio of (1.4x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Quanterix Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Quanterix Margins & Growth Rates
Quanterix grew revenue by 22% but EBITDA decreased by 37% in the last fiscal year.
In the most recent fiscal year, Quanterix reported gross margin of 47%, EBITDA margin of (32%), and net margin of (77%).
Quanterix Margins
Quanterix Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Quanterix Operational KPIs
Quanterix's revenue per employee in the last FY averaged $1.0M, while opex per employee averaged $1.3M for the same period.
Quanterix's Rule of 40 is 6% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Quanterix's Rule of X is 40% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
Quanterix Competitors
Quanterix competitors include Zepp Health, Nyxoah, NN, Paxman, C-Rad, JETEMA Co., Fonar, Onyx Healthcare, Emvision and CROSSJECT.
Most Quanterix public comparables operate across Medical Devices, DeepTech and HealthTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 1.2x | 1.0x | (11.8x) | (24.5x) | |||
| 11.8x | 5.8x | (1.5x) | (1.6x) | |||
| 0.8x | 0.8x | 6.8x | 6.4x | |||
| 3.4x | 3.1x | 36.8x | 23.9x | |||
| 2.2x | 2.2x | 17.8x | 15.7x | |||
| 4.1x | — | 27.3x | — | |||
| 1.0x | — | 5.6x | — | |||
| 2.7x | — | 24.3x | — | |||
This data is available for Pro users. Sign up to see all Quanterix competitors and their valuation data. Start Free Trial | ||||||
Quanterix Funding History
Before going public, Quanterix raised $55M in total equity funding, across 2 rounds.
Quanterix Funding Rounds
Quanterix M&A Activity
Quanterix has acquired 3 companies to date.
Last acquisition by Quanterix was on January 10th 2025. Quanterix acquired Akoya Biosciences for $286M (EV/Revenue multiple of ).
Latest Acquisitions by Quanterix
| Description | Akoya Biosciences is a Marlborough, Massachusetts-based spatial biology provider offering end-to-end high-parameter tissue analysis platforms including PhenoCycler for over 60-plex imaging in clinical trials and CODEX for 40-plus biomarker discovery. Its solutions advance immuno-oncology, cancer, autoimmune, and neurology research through multiplexed immunofluorescence. | Emission iNC is a Boston-based biotech firm providing multiplex assay instruments and reagents for high-throughput protein analysis, enabling labs to run assays at lower costs with higher sensitivity for research in proteomics and diagnostics. | UmanDiagnostics manufactures neurofilament light chain ELISA kits and antibodies for biomarker research in ALS and Alzheimer's. Umea-based since 1990, the Swedish firm supplies 1,000+ labs worldwide, with kits detecting Nf-L at 30 pg/mL sensitivity used in Roche and Biogen trials. |
| HQ Country | |||
| HQ City | Boston, MA | Austin, TX | Umeå |
| Deal Date | 10 Jan 2025 | 17 Dec 2024 | 26 Jun 2019 |
| Valuation | $286M | $70M | $23M |
| EV/Revenue | |||
| EV/EBITDA | |||
This data is available for Pro users. Sign up to see all Quanterix acquisitions and their M&A valuation multiples. Start Free Trial | |||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Quanterix
| When was Quanterix founded? | Quanterix was founded in 2007. |
| Where is Quanterix headquartered? | Quanterix is headquartered in United States. |
| How many employees does Quanterix have? | As of today, Quanterix has over 136 employees. |
| Who is the CEO of Quanterix? | Quanterix's CEO is Everett V. Cunningham. |
| Is Quanterix publicly listed? | Yes, Quanterix is a public company listed on Nasdaq. |
| What is the stock symbol of Quanterix? | Quanterix trades under QTRX ticker. |
| When did Quanterix go public? | Quanterix went public in 2017. |
| Who are competitors of Quanterix? | Quanterix main competitors include Zepp Health, Nyxoah, NN, Paxman, C-Rad, JETEMA Co., Fonar, Onyx Healthcare, Emvision, CROSSJECT. |
| What is the current market cap of Quanterix? | Quanterix's current market cap is $127M. |
| What is the current revenue of Quanterix? | Quanterix's last 12 months revenue is $151M. |
| What is the current revenue growth of Quanterix? | Quanterix revenue growth (NTM/LTM) is 17%. |
| What is the current EV/Revenue multiple of Quanterix? | Current revenue multiple of Quanterix is 0.4x. |
| Is Quanterix profitable? | No, Quanterix is not profitable. |
| What is the current EBITDA of Quanterix? | Quanterix has negative EBITDA and is not profitable. |
| What is Quanterix's EBITDA margin? | Quanterix's last 12 months EBITDA margin is (25%). |
| What is the current EV/EBITDA multiple of Quanterix? | Current EBITDA multiple of Quanterix is (1.6x). |
| How many companies Quanterix has acquired to date? | As of May 2026, Quanterix has acquired 3 companies. |
| What was the largest acquisition by Quanterix? | $286M acquisition of Akoya Biosciences on 10th January 2025 was the largest M&A Quanterix has done to date. |
| What companies Quanterix acquired? | Quanterix acquired Akoya Biosciences, Emission iNC, and UmanDiagnostics. |
| In how many companies Quanterix has invested to date? | Quanterix hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Quanterix
Lists including Quanterix
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

